The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EMN 2021 | COVID-19 outcomes for myeloma patients receiving lenalidomide maintenance
Meral Beksac, MD, Ankara University, Ankara, Turkey, gives an overview of study investigating the outcomes of patients with COVID-19 infections who are receiving lenalidomide maintenance therapy, as presented at EMN 2021. Data was analyzed from 48 patients with multiple myeloma who were also diagnosed with a COVID-19 infection. The study found that patients receiving lenalidomide maintenance therapy had a COVID-19 infection fatality rate of 30.4%, compared to a rate of 48% for patients who were not receiving lenalidomide maintenance therapy. This interview took place during the 2021 European Myeloma Network (EMN) congress.
